SS = Sigma sample and is used as a quality control The first set (ADC1) used for biomarker development consisted of serum and plasma samples obtained from 52 stages I to IV NSCLC adenocarcinoma patients (52 plasma and 49 serum), and 31 healthy controls (31 pairs of serum and plasma) for a total of 163 samples. This set was regarded as the training set for biomarker discovery and classifier development. A second, independent case control study (ADC2) consisting of serum and plasma samples collected from 43 stage I to IV NSCLC adenocarcinoma patients and 43 healthy controls (total 172 samples) was used as an independent test set for biomarker evaluation. A limitation of this study is the relatively small sample size for each cohort 52 cases, 31 controls for ADC1, and 43 cases and 43 controls for ADC2 because patient variability can be a big factor in smaller studies.
[doi:10.25345/C5H94S]
[dataset license: CC0 1.0 Universal (CC0 1.0)]
Keywords: blood ; serum ; GCMS ; lung cancer
Principal Investigators: (in alphabetical order) |
Oliver Fiehn, University of California, Davis, N/A |
Submitting User: | aaksenov |
Number of Files: | |
Total Size: | |
Spectra: | |
Subscribers: | |
Owner | Reanalyses | |
---|---|---|
Experimental Design | ||
Conditions:
|
||
Biological Replicates:
|
||
Technical Replicates:
|
||
Identification Results | ||
Proteins (Human, Remapped):
|
||
Proteins (Reported):
|
||
Peptides:
|
||
Variant Peptides:
|
||
PSMs:
|
||
Quantification Results | ||
Differential Proteins:
|
||
Quantified Proteins:
|
||
Browse Dataset Files | |
FTP Download Link (click to copy):
|